Salvadó, Gemma
Milà-Alomà, Marta
Shekari, Mahnaz
Ashton, Nicholas J.
Operto, Grégory
Falcon, Carles
Cacciaglia, Raffaele
Minguillon, Carolina
Fauria, Karine
Niñerola-Baizán, Aida
Perissinotti, Andrés
Benedet, Andréa L.
Kollmorgen, Gwendlyn
Suridjan, Ivonne
Wild, Norbert
Molinuevo, José Luis
Zetterberg, Henrik
Blennow, Kaj
Suárez-Calvet, Marc
Gispert, Juan Domingo http://orcid.org/0000-0002-6155-0642
,
Funding for this research was provided by:
“la Caixa” Foundation (LCF/PR/GN17/50300004)
Tribeca Film Institute (TriBEKa-17-519007)
Universities and Research Secretariat (2017-SGR-892)
Spanish Ministry of Science and Innovation (RYC-2013-13054)
Instituto de Salud Carlos III (PI19/00155)
Spanish Ministry of Science and Innovation (IJC2018-037478-I)
Eurofingers (733051102)
Swedish Research Council (2018-02532)
European Research Council (681712)
Swedish State Support for Clinical Research (ALFGBG-720931)
Alzheimer's Drug Discovery Foundation (201809-2016862)
AD strategic fund (ADSF-21-831376-C, ADSF-21-831381-C, ADSF-21-831377-C)
Olay Thon Fundation (FO2019-0228)
Horizon 2020 (860197)
UK Dementia Research Institute (2017-00915)
Swedish Alzheimer Foundation (AF-742881)
Hjärnfonden (FO2017-0243)
Skåne County Council's Research and Development Foundation (ALFGBG-715986)
European Union (JPND2019-466-236)
National Institutes of Health (1R01AG068398-01)
Article History
Received: 10 December 2021
Accepted: 28 June 2022
First Online: 18 July 2022
Declarations
:
: The ALFA study and the PET sub-study protocols have been approved by an independent Ethics Committee Parc de Salut Mar Barcelona and registered at Clinicaltrials.gov (ALFA Identifier: NCT02485730; PET sub-study Identifier:NCT02685969). Both studies have been conducted in accordance with the directives of the Spanish Law 14/ 2007, of 3rd of July, on Biomedical Research (Ley 14/ 2007 de Investigación Biomédica). All participants provided written informed consent to participate in the study.
: JLM is currently a full-time employee of Lundbeck and has before served as a consultant or at advisory boards for the following for-profit companies or has given lectures in symposia sponsored by the following for-profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, ProMIS Neurosciences, NovoNordisk, Zambón, Cytox, and Nutricia. MSC has given lectures in symposia sponsored by Roche Diagnostics, S.L.U. GK and NW are full-time employees of Roche Diagnostics GmbH. IS is a full-time employee and shareholder of Roche Diagnostics International Ltd. HZ has served at scientific advisory boards and/or as a consultant for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx, and Red Abbey Labs; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, and Biogen; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, and JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. The rest of the authors have no conflict of interest to declare. ELECSYS, COBAS, and COBAS E are trademarks of Roche. The Roche NeuroToolKit robust prototype assays are for investigational purposes only and are not approved for clinical use.